Change in BMI · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Abdominal pain frequency or change in frequency · adults and children with cystic fibrosis
Summary of findings: ECM (Creon®) showed no clear difference in frequency of bowel symptoms: proportion of days with abdominal pain compared with a different ECM (low certainty).
1 finding from 1 review
CFA: CFA (%) · adults and children with cystic fibrosis
Summary of findings: ECM (Creon®) showed no clear difference in CFA: CFA (%) compared with a different ECM (moderate certainty).
1 finding from 1 review
Adverse events · adults and children with cystic fibrosis
1 finding from 1 review
Pulmonary exacerbations · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mean GI symptom scores · People with urological (prostate) and gynaecological (cervical) cancer
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Acute and late GI toxicity (grade 2+) · People with urological (prostate) and gynaecological (cervical) cancer
1 finding from 1 review
Diarrhoea (grade 2+) · People with urological (prostate) and gynaecological (cervical) cancer
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
QoL · People with urological (prostate) and gynaecological (cervical) cancer
1 finding from 1 review
no estimate extracted
0 participants
GRADE not reported
Muscle soreness · mainly physically active individuals1 partaking in exercise2 designed to produce delayed onset muscle soreness
Summary of findings: antioxidants showed no clear difference in muscle soreness compared with placebo (low certainty).
5 findings from 1 review
no estimate extracted
21 studies · 525 participants
Low
no estimate extracted
41 studies · 936 participants
Moderate
no estimate extracted
45 studies · 1047 participants
Low
Show 2 more findings
Subjective recovery · mainly physically active individuals1 partaking in exercise2 designed to produce delayed onset muscle soreness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Adverse events · mainly physically active individuals1 partaking in exercise2 designed to produce delayed onset muscle soreness
1 finding from 1 review
Response to treatment at 5 to 6 months ‐ overall response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ overall response compared with placebo (high certainty).
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in response to treatment at 6 months ‐ complete response compared with cidofovir (moderate certainty).
1 finding from 1 review
Pain ‐ Any grade · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in pain ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Fatigue · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher fatigue ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Headache · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod probably leads to higher headache ‐ any grade compared with cidofovir (moderate certainty).
1 finding from 1 review
Total serious adverse events · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in total serious adverse events compared with cidofovir (moderate certainty).
1 finding from 1 review
Treatment discontinuation · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod showed no clear difference in treatment discontinuation compared with cidofovir (moderate certainty).
1 finding from 1 review
Complete response · women with usual‐type vulval intraepithelial neoplasia
Summary of findings for imiquimod leads to higher response to treatment at 5 to 6 months ‐ complete response compared with placebo (high certainty).
2 findings from 1 review